Orforglipron dosing & administration

Name: Orforglipron Injection Dosage & Protocol
Creator: Michael Carroll

First oral non-peptide GLP-1 receptor agonist for diabetes and obesity

Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards

6 – 36 mgSuggested dose

Once daily, any time of dayFrequency

OralRoute

Ongoing/indefiniteCycle length

Dosing

How much do I take?

Oral: Taken by mouth as a capsule, tablet, or liquid.

Bioavailability Varies by compound — many peptides are largely broken down in the gut, so little reaches the blood intact; some small molecules absorb well.

Titration schedule

Lowest of three phase-3 maintenance doses

6 mg once daily

Frequency

Once daily, any time of day

Duration

Lowest of three phase-3 maintenance doses

Lowest maintenance dose in the ATTAIN-1 phase-3 obesity trial; reached via gradual monthly titration from 1 mg [6]. Taken without food/water restrictions.

Maintained for 72-week trial duration

12 mg once daily

Frequency

Once daily, any time of day

Duration

Maintained for 72-week trial duration

Mid-level maintenance dose in ATTAIN-1 phase-3 obesity trial [6].

Maintained for 72-week trial duration

36 mg once daily

Frequency

Once daily, any time of day

Duration

Maintained for 72-week trial duration

Highest phase-3 dose; produced ~12.4% body-weight reduction at 72 weeks in ATTAIN-1 [6]. Investigational, not yet FDA-approved.

Timing

Best time to take

Take Orforglipron at the same time each day for consistent blood levels. Morning dosing with breakfast is often preferred, but follow your healthcare provider's specific instructions.

With food?

Orforglipron can typically be taken with or without food. Taking it with a light meal may help reduce any GI discomfort. Avoid taking with grapefruit juice or high-fat meals unless specifically directed.

If stacking

Orforglipron should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.

Adjusting your dose

Increase if

You've tolerated the current dose for the recommended period without significant side effects
Therapeutic goals haven't been met at the current dose level
Your healthcare provider recommends dose escalation based on your response
Lab work or clinical assessments support a higher dose

Decrease if

Side effects are bothersome or impacting daily life despite management strategies
You experience any signs of an adverse reaction
Lab results indicate the need for dose reduction
Your healthcare provider recommends a lower dose based on your response

Signs of right dose

Therapeutic goals being met with minimal side effects
Stable and consistent response to treatment
Lab values or clinical markers trending in the right direction
Good tolerance with manageable or absent side effects

OrforglipronOnce daily, any time of day

How much peptide is in your bottle?

Look at the label on the vial. It’s the number next to mg — like "5 mg".

Type a number to continue.

Administration

How do I use it?

Reconstitution

What you need

Orforglipron in its prescribed formClean, dry storage containerMeasuring device if applicable (oral syringe, measuring cup)Calendar or reminder app for dosing schedule

Injection

Route

Orforglipron is administered oral—no injection required

Best sites

Not applicable—this is not an injectable formulation

Storage

Before reconstitution

Store Orforglipron in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.

After reconstitution

Once reconstituted, Orforglipron should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.

Signs of degradation — discard the vial

Solution appears cloudy, discolored, or contains visible particles (should be clear)Product has been exposed to temperatures outside the recommended storage rangeProduct has been frozen (unless specifically designed for freeze-thaw stability)Expiration date has passed or reconstituted solution has exceeded its use-by dateUnusual odor, color change, or visible contamination

Sample daily schedule

As prescribed (once daily)

As prescribed by your healthcare provider injection

Site: oral—rotate sites if applicable

Maintain a consistent schedule for optimal results with Orforglipron. Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.

Safety

Is it safe?

Side effects

Commonly reported: Nausea, Constipation, Diarrhea, Vomiting

Less common: Heart Rate Increase

Stop and seek help if

Severe or worsening side effects that don't improve with dose adjustment or supportive care
Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
Your healthcare provider recommends discontinuation based on your clinical response
Development of any new medical condition that may be contraindicated with Orforglipron
Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
Abnormal lab results or clinical markers that suggest adverse effects

Orforglipron should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.

Flagged pairings

Injectable GLP-1 Receptor Agonists — Redundant GLP-1R activation with no additional benefit and increased gastrointestinal adverse events
DPP-4 Inhibitors — Overlapping incretin pathway stimulation provides minimal additional efficacy when combined with a direct GLP-1R agonist
Sulfonylureas — Increased hypoglycemia risk from non-glucose-dependent insulin secretion combined with GLP-1R-mediated insulin release